Drug Profile
SPL 334
Alternative Names: GSNORi - SAJE Pharma; SPL-334; SPL-334.1Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer SAJE Pharma
- Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Heart failure therapies; Hepatoprotectants; Small molecules
- Mechanism of Action Glutathione-independent formaldehyde dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Asthma; Idiopathic pulmonary fibrosis; Inflammation; Parkinson's disease
Highest Development Phases
- Preclinical Asthma; Idiopathic pulmonary fibrosis; Inflammation; Myocardial infarction; Non-alcoholic fatty liver disease
- Discontinued Parkinson's disease
Most Recent Events
- 31 Aug 2023 Preclinical development in Asthma in USA (PO) (SAJE Pharma pipeline; August 2023)
- 31 Aug 2023 Preclinical development in Idiopathic-pulmonary-fibrosis in USA (PO) (SAJE Pharma pipeline; August 2023)
- 31 Aug 2023 Preclinical development is ongoing in Inflammation in USA (Intraperitonial) (SAJE Pharma pipeline; August 2023)